CHEMCLIN DIAGNOSTICS CO., LTD. Financials Chemclin Diagnostics Co., Ltd.
Equities
688468
CNE100005311
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.53 CNY | -1.05% |
|
-4.44% | -30.21% |
| 05-03 | Chemclin Diagnostics Launches Homegrown Immunodetection Kits | MT |
| 04-29 | Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 7,186 | 3,797 | 4,327 |
| Enterprise Value (EV) 1 | 6,286 | 2,825 | 3,643 |
| P/E ratio | 48.4 x | 24.9 x | 29.2 x |
| Yield | 0.95% | 3.66% | - |
| Capitalization / Revenue | 15.3 x | 8.16 x | 9.72 x |
| EV / Revenue | 13.4 x | 6.07 x | 8.18 x |
| EV / EBITDA | 35 x | 16.2 x | 19.7 x |
| EV / FCF | 109 x | 30.3 x | -22.9 x |
| FCF Yield | 0.91% | 3.3% | -4.37% |
| Price to Book | 5.62 x | 2.75 x | 3.12 x |
| Nbr of stocks (in thousands) | 401,000 | 401,000 | 401,000 |
| Reference price 2 | 17.92 | 9.470 | 10.79 |
| Announcement Date | 4/27/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 454.7 | 418.2 | 470.8 | 465.3 | 445.3 |
| EBITDA 1 | 182.7 | 156.1 | 179.7 | 174.8 | 185 |
| EBIT 1 | 141.3 | 114.1 | 137.1 | 135.1 | 147.8 |
| Operating Margin | 31.07% | 27.28% | 29.13% | 29.04% | 33.19% |
| Earnings before Tax (EBT) 1 | 159.6 | 135.4 | 162.2 | 177.4 | 166.1 |
| Net income 1 | 140.6 | 117 | 142.8 | 152.6 | 147.4 |
| Net margin | 30.92% | 27.98% | 30.32% | 32.8% | 33.09% |
| EPS 2 | 0.7000 | 0.3300 | 0.3700 | 0.3800 | 0.3700 |
| Free Cash Flow 1 | 93.9 | 6.059 | 57.47 | 93.29 | -159.1 |
| FCF margin | 20.65% | 1.45% | 12.21% | 20.05% | -35.73% |
| FCF Conversion (EBITDA) | 51.39% | 3.88% | 31.99% | 53.37% | - |
| FCF Conversion (Net income) | 66.79% | 5.18% | 40.26% | 61.12% | - |
| Dividend per Share 2 | 0.2778 | - | 0.1700 | 0.3470 | - |
| Announcement Date | 3/18/21 | 3/18/21 | 4/27/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 583 | 553 | 900 | 973 | 684 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | 93.9 | 6.06 | 57.5 | 93.3 | -159 |
| ROE (net income / shareholders' equity) | 17.1% | 13.3% | 13.2% | 11.5% | 10.6% |
| ROA (Net income/ Total Assets) | 9.55% | 7.13% | 7.03% | 5.59% | 5.42% |
| Assets 1 | 1,473 | 1,641 | 2,030 | 2,731 | 2,721 |
| Book Value Per Share 2 | 2.410 | 2.460 | 3.190 | 3.440 | 3.460 |
| Cash Flow per Share 2 | 0.2900 | 0.6200 | 0.7800 | 0.8500 | 1.120 |
| Capex 1 | 55.2 | 83.3 | 72.5 | 125 | 301 |
| Capex / Sales | 12.15% | 19.92% | 15.41% | 26.93% | 67.67% |
| Announcement Date | 3/18/21 | 3/18/21 | 4/27/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -30.21% | 422M | |
| -4.62% | 12.18B | |
| +8.48% | 5.96B | |
| +27.58% | 5.45B | |
| -6.28% | 4.34B | |
| -52.84% | 3.18B | |
| +12.93% | 2.75B | |
| +30.88% | 2.3B | |
| -3.80% | 2.28B | |
| -4.64% | 1.92B |
- Stock Market
- Equities
- 688468 Stock
- Financials Chemclin Diagnostics Co., Ltd.
